Published on : Jul 21, 2016
On Wednesday, 20th July, the researches of Mayo Clinic Center for Individualized Medicine have come up with a lucrative new way of treating and monitoring the recurrence of cancer of the ovaries. This is a hard to detect disease that has caused a number of deaths in the past few years. As per George Vasmatzis, who is a Ph.D in the Department of Laboratory Medicine and Pathology at Mayo Clinic, the liquid biopsies from DNA sequencing and blood tests may help in the detection of a recurring ovarian cancer prior to the occurrence of a tumor.
This may result in more effective treatment and an earlier intervention for this type of cancer. As put by Dr. Vasmatzis, doctors need not wait for the growth of the tumor for getting a DNA sample, instead this significant discovery has made it possible for doctors to detect the recurrence of this type of cancer even before the other diagnostic methods utilized. He also states that liquid biopsies can be repeated for monitoring the cancer progression. This will result in a better treatment process all through.
This study took place on 10 patients suffering from ovarian cancer with advanced stages. In these cases, blood was taken after and before the surgery and DNA from tissue samples of the tumor was compared to the DNA from liquid biopsies by utilizing mate-pair sequencing. Within this study, the blood taken after and before surgery as well as the surgical tissue was employed for the identification of DNA fragments having abnormal junctions. These fragments can only be observed in the DNA of the patient’s tumor.
After this, the next-generation mate-pair sequencing was employed for the identification of particular DNA changes in the tumor in order to create a customized monitoring panel for the liquid biopsy. In case the post-surgery DNA did match with that of the tumor, the patients were found to have a recurrence of the cancer of the ovary and vice versa.